{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Hematologic Cancers

Activity Steps

1 Activity
2 Take Test 3Certificate

Purpose of Activity

To present the latest information about advances in treatments for hematologic cancers.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify recent advances in the use of monoclonal antibodies to treat multiple myeloma.
  2. Recognize the role of hematopoietic stem cell transplantation (HSCT) in treating patients with Cutaneous T-Cell Lymphoma (CTCL) and chronic myelogenous leukemia (CML).
  3. Discern appropriate monitoring guidelines to assess the response of patients to tyrosine kinase inhibitors (TKIs)

Disclosures

The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.

Price: $21.95

Credits:

  • ANCC 2.0 CH
  • DC - BON 2.0 CH
  • KY-BON 2.0 CH
  • GA - BON 2.0 CH

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, #50-1223, Florida Board of Nursing, #50-1223, and Georgia Board of Nursing, #50-1223. Your certificate is valid in all states.







Planner
Test Code: OT1215
Published: Dec 2015
Expires: 12/31/2026
Sources: Oncology Times
Required Passing Score: 10/13 (76%)
Authors: Mark L. Fuerst; Sarah DiGiulio; Heather Lindsey
Categories: Cancer , Drug Therapy , Hematology , Oncology
Specialties: Oncology
Topics: Chemotherapy , Hematopoietic Stem Cell Transplantation , Leukemia , Lymphoma , Multiple Myeloma